NEW CHEMICAL ENTITIES

BACHEM

PIONEERING PARTNER FOR PEPTIDES
With almost 50 years of expertise in peptide synthesis, a track record in process development, large-scale manufacturing and outstanding product quality we hold a leading position.
Bachem is the leading independent supplier of peptidic active pharmaceutical ingredients (APIs) for the human and veterinary pharmaceutical market. Since its foundation in 1971, Bachem’s concepts and technologies pioneered the industrial peptide manufacturing. Our history of firsts drive us to continue developing innovations and we offer a full range of integrated services to bring our partner’s breakthroughs to market.

- Process development and custom manufacturing
- From discovery to commercialization
- Milligrams to tons
- Quality you can trust
- Dedicated project management team
- Excellent service and support
- cGMP manufacturing facilities in the USA and in Europe
Bachem facilities are located in Switzerland, Europe and in the USA.

All cGMP manufacturing sites are inspected by the FDA and national authorities.
Bachem's pipeline contains more than 150 preclinical and clinical projects. They all have promising potential: in the last two years, a number of products in phase III trials received marketing authorization and phase II projects progressed to phase III clinical trials. Our portfolio is completed by small molecule projects and peptide conjugated NCEs.
BACHEM’S PORTFOLIO of products and services...

**GENERIC APIs**
- peptide and small molecule generics
- supply of commercial quantities
- reputation for sustained quality & supply
- high-demand APIs available from stock
- close and long term partnerships

**NCEs**
- process development, optimization and validation
- comprehensive analytical services
- supply of cGMP material for all clinical phases
- cGMP-manufacturing of APIs for commercial supply
CATALOG PRODUCTS
- more than 6500 products available online
- peptides, amino acids, inhibitors, substrates
- fast & easy ordering @ shop.bachem.com
- bulk quantities according to your needs
- excellent customer and technical support

CUSTOM SYNTHESIS
- from discovery stages to early clinical candidates
- strong focus on quality and timely execution
- development of synthetic routes for scale up
- best industry practice
- highly motivated and experienced team

...from R&D to commercial supply
Flexible solutions for successful development and production of your product are provided by our dedicated facilities.

Bachem offers cGMP contract manufacturing of active pharmaceutical ingredients (APIs) and advanced intermediates from clinical trial material to product launch quantities and commercialization.
Custom Manufacturing
- Manufacturing of peptide and small molecule APIs (GMP and non-GMP)
- Feasibility studies
- Process development and scale-up
- Process validation

Quality Control
- Analytical method development
- Analytical method validation
- Forced degradation studies
- Indicative stability studies
- ICH stability studies
- Follow-up stability testing

Regulatory Support
- Preparation of CMC documentation
- Preparation and submission of DMFs
- Consulting and regulatory support
Bachem’s quality management system covers the entire production process, from starting materials to production, packaging and delivery of the final product.

Regular audits by customers and authorities systematically verify our quality in terms of equipment, processes and products. Successful inspections by more than 50 customer audits per year and by national authorities confirm our high quality standard and our compliance with the requirements for Good Manufacturing Practices (cGMP).

WE MANUFACTURE PEPTIDES WITH EXCELLENT BATCH-TO-BATCH REPRODUCIBILITY.

THIS GUARANTEES CONSISTENT GOOD QUALITY AND MAKES BACHEM A RELIABLE PARTNER FOR YOU.
REGULATORY COMPLIANCE

• API manufacturing and related services under cGMP
• FDA-inspected since 1997
• Authorized by national authorities (e.g. Swissmedic)
• ISO 13485 certified manufacturing sites in Vista, U.S. and St. Helens, UK
PARTNERSHIP

Bachem has established long-term partnerships, being a reliable, independent and financially solid company. Through close collaboration, we enable our customers to bring unique and life changing drug products to the market.

«OUR PARTNERS CAN TRUST IN OUR SUPPORT AND GUIDANCE THROUGHOUT ALL STAGES FROM EARLY DEVELOPMENT, THROUGH CLINICAL TRIALS AND BEYOND COMMERCIALIZATION.»

«Theratechnologies is very pleased to be working with Bachem as a supplier of Tesamorelin. The experience has been very collaborative and contributed to the success of the development program all the way up to market approval. Certainly, Bachem’s expertise in peptides, their professional project management and dedication to quality gives us great confidence in knowing we are with the right partner.»
Pierre Perazzelli, V.P. Pharmaceutical Development Theratechnologies, Inc.

«As President and CEO of an emerging biopharmaceutical company, the selection process of a GMP API manufacturer was necessarily exhaustive. We have been pleased with the expeditious development activities and subsequent delivery of our novel API by Bachem. Moreover, Bachem continues to provide professional and timely post-production service.»
Paul Gunn, President & CEO Soricimed BioPharma Inc.

«When entering phase III with our lead product, we want to work with the best in class to assure optimal technical and regulatory support in order to get our therapeutic HPV product to the market as soon as possible. Bachem is our partner of choice since it has a proven track record, as well as the skills and the range of services we need.»
Gerard Platenburg, CEO ISA Pharmaceuticals B.V.
PROJECT MANAGEMENT

As the world’s leading peptide manufacturer, we are currently involved in more than 150 cGMP projects centered around New Chemical Entities.

Each project is handled by a dedicated project manager who is ensuring that the timelines, budget, and overall goals and deliverables of the project are carefully monitored and met.

All of our project managers are science-minded and experienced in peptide-based NCE development. Their knowledge of phase appropriate milestones paired with their consultive nature can be a huge asset to early stage pharma and biotech companies that don’t have the luxury of an experienced in-house peptide development team.

Your project manager will partner with you and act as an internal voice for your company to guarantee that we meet all your needs and expectations and help ensure you tap into Bachem’s almost 50 years of peptide manufacturing expertise.

«IN CLOSE COLLABORATION WITH YOU, WE UNDERSTAND HOW WE CAN BEST SUPPORT YOUR PROJECTS.

WE PLAN AHEAD, WE ARE FAST AND FLEXIBLE, AND WE OFFER THE NECESSARY REGULATORY SUPPORT.»
REGULATORY SUPPORT

- We provide chemistry, manufacturing, and controls (CMC) information to customers for inclusion in their regulatory submissions or directly to regulatory authorities.

- Our service includes the compilation of the documents and we offer support regarding regulatory requests.

- Through our expertise we enable our partners to meet the regulatory filing requirements from drug development through commercialization.
BACHEM’S SERVICES FOR NCE-PROJECTS IN THE PROCESS OF DRUG DEVELOPMENT

<table>
<thead>
<tr>
<th>DISCOVERY</th>
<th>DEVELOPMENT</th>
<th>LAUNCH &amp; MARKETED PRODUCT</th>
</tr>
</thead>
<tbody>
<tr>
<td>RESEARCH</td>
<td>PRECLINICAL</td>
<td>CLINICAL I</td>
</tr>
<tr>
<td>CLINICAL I</td>
<td>CLINICAL II</td>
<td>CLINICAL III</td>
</tr>
<tr>
<td>MARKET SUPPLY</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

API MANUFACTURING
- non-GMP batch
- GMP batches
- Large Scale Manufacturing

PROCESS DEVELOPMENT
- process development
- scale up
- process validation

ANALYTICS
- method development
- reference standard
- method validation
- release
- Stability
  - stress test
  - indicative stability studies
  - ICH stability studies
  - Follow up stability studies (FUST)

REGULATORY DOCUMENTS
- CMC Doc. phase I
- CMC Doc. phase II
- CMC Doc. phase III
- DMF

FROM IND (IMPD) TO NDA (MAA)
PRECLINICAL

CHEMICAL DEVELOPMENT & API SYNTHESIS
Feasibility study/manufacturing of non-GMP material
- process development (synthesis and purification)
- obtained material can be used for toxicology studies*, stress testing, formulation studies and initial analytical method development
- technology transfer from non-GMP to GMP

GMP manufacturing
- starts at the end of the preclinical phase
- GMP material is mandatory for phase I clinical trials

ANALYTICAL DEVELOPMENT

STABILITY/ANALYTICS
HPLC method development

Stress testing (strongly recommended)
- forced degradation, influence of temperature and moisture in the solid state
- hygroscopicity, photostability
- essential to get information for determining handling, shipment and storage conditions
- prerequisite for the analytical method development of the HPLC purity method

REGULATORY DOCUMENTS
Preparation of CMC documentation to enter phase I

CLINICAL PHASE I

MANUFACTURING
GMP manufacture
- process development
- scale-up

STABILITY
Indicative stability studies (recommended)
- custom protocols available
- stability under different storage conditions at defined periods of time

ANALYTICS
Validation of analytical methods
- purity and assay
Characterization of reference standard
- portioning of solid reference material into vials (individually labeled and sealed)
- release by QA with Certificate of Analysis
- storage under controlled conditions, regularly tested

REGULATORY DOCUMENTS
Preparation of CMC documentation to enter phase II

CLINICAL PHASE II & III

MANUFACTURING
GMP manufacture
- scale-up
MBPR
- manufacturing of confirmation batch according to master batch production record (MBPR)

Process validation
- manufacturing of 3 validation batches (demonstrate reproducibility and consistency of process)
- batch size should represent batch size of post-market approval
- validated analytical methods are prerequisite for the process validation

STABILITY
ICH stability studies
- at least 6 months data required for DMF

ANALYTICS
Validation of analytical methods
- validation according to ICH guideline Q2(R1)
- e.g., peptide content, purity, water content, acetate content, residual solvents, bioburden
- must be completed prior to release testing of the validation batches

REGULATORY DOCUMENTS
Preparation of CMC documentation for phase III
Preparation of DMF
- at least 6 months data of ICH stability study required
- open part of CMC/DMF provided to customer, closed part sent directly to authorities
For almost 50 years, Bachem holds a leading position in the process development and manufacturing of peptides.
BACHEM YOUR PARTNER FOR PEPTIDE-BASED APIs

...FOR DECADES AND BEYOND
Visit our website | www.bachem.com
or shop online | shop.bachem.com

All information is compiled to the best of our knowledge.
We cannot be made liable for any possible errors or misprints.
Some products may be restricted in certain countries.